Abstract library

68 results for "Dhar".
#3077 Insights into the Practice Patterns, Challenges and the Role of a Shared Care Model in the Management of Neuroendocrine (NET) Patients in the Community
Introduction: Management of NET patients often involves a multidisciplinary approach,requiring collaboration between referring oncologists,surgeons,endocrinologists locally and NET specialty centers (NSC).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Yelamanchili Radhika
Authors: Radhika Y, Chan D, Thawer A, Lo D, ...
#28 Prognostic Clinicopathologic Factors in Longitudinally Followed Patients with Metastatic Small Bowel Carcinoid
Introduction: Neuroendocrine tumors demonstrate heterogeneous behavior based upon site of origin and specific histology. Even after controlling for anatomic location, disease stage and histologic grade, registry studies show persistent diversity of outcome in patients with midgut carcinoid.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Mr. Thomas Curran
#222 Results of Resection and Predictors of Outcome of Pancreatic Neuroendocrine Tumors
Introduction: Pancreatic neuroendocrine tumors (PNET) are uncommon with the incidence increasing significantly over the last decade. Surgical resection remains the only therapeutic option.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Mr Ravi Marudanayagam
#332 Impact of Baseline Ki-67 index and Other Baseline Characteristics on Outcome in a Study of Sunitinib (SU) for the Treatment of Advanced, Progressive Pancreatic Neuroendocrine Tumor (NET)
Introduction: Baseline Ki-67 index and other characteristics may influence outcome in patients (pts) with pancreatic NET; however, the value of Ki-67 and others have not been evaluated prospectively in trials.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Eric Raymond
#395 Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) in North American Cohort of Patients with Metastatic Well-Differentiated Neuroendocrine Tumors (mNETs)
Introduction: PRRT is an accepted treatment in Europe for patients (pts) with mNETs, but considered investigational in the USA.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Boris Naraev
#402 Single-Center Treatment Outcomes in Patients (pts) with High Grade Neuroendocrine Carcinoma of the Uterine Cervix (cNEC)
Introduction: cNEC is a rare and aggressive cancer; the best treatment is unknown.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Boris Naraev
#433 Clinical and Prognostic Features of Rectal Neuroendocrine Tumors
Introduction: Rectal neuroendocrine tumors (NETs) are among the most common NETs.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Brett M Weinstock
Keywords: net
#439 Chromogranin A (CgA) and Pancreastatin (PcSt) as Predictors of Peptide Receptor Radionuclide Therapy (PRRT) Outcomes in Patients with Metastatic Well-Differentiated Neuroendocrine Tumors (mNETs)
Introduction: CgA and PcSt are widely used in assessing response to treatment in mNETs.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Nancy Sharma
#457 Comparison of Transarterial Liver-Directed Therapies (LDT) for Low-Grade Metastatic Neuroendocrine Tumors (mNETs)
Introduction: Transarterial LDT can ameliorate symptoms and improve time to tumor progression (TTP) in mNETs.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Eric Engelman
#779 Results of Pancreatic Surgery for Neuroendocrine Tumors: Single Center Experience with No Perioperative Mortality
Introduction: Pancreatic neuroendocrine tumors (p-NET).
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Clinical cases/reports
Presenting Author: Dr Roberto Valente
Keywords: p-NET, surgery